Navigation Links
Cordex Pharma Forms Heart Failure Medical Advisory Board
Date:2/11/2009

Medicine and Professor of Physiology at Boston University School of Medicine. He is also the Chief of Cardiovascular Medicine, Director of the Myocardial Biology Unit, Director of the Cardiomyopathy Program and Co-Director of the Cardiovascular Center at Boston Medical Center.

Howard J. Eisen, M.D., F.A.C.C., F.A.C.P., F.A.H.A., is the Thomas J. Vischer, Professor of Medicine and Chief of the Division of Cardiology at Drexel University, College of Medicine. He is also Director of the Drexel Center for Cardiovascular Disorders and The Center for Advanced Heart Failure Care at Hahnemann University Hospital.

Douglas L. Mann, M.D., F.A.C.C., F.A.C.P., is Chief, Division of Cardiology, Lewin Chair and Professor of Medicine, Washington University in St. Louis, Cardiologist-in-Chief, Barnes Jewish Hospital.

Richard P. Schwarz, Ph.D., is President of CV Ventures, LLC, a consulting firm specialized in the design and execution of clinical trials and an Adjunct Professor at University of Miami.

Jonathan S. Stamler, M.D. is the George Barth Geller Professor of Research in Cardiovascular Diseases and Professor of Medicine and Biochemistry at Duke University.

Dr. Hare stated, "I am pleased to have a group of distinguished colleagues joining me in support of the clinical development program of CDP-1050. Their remarkable clinical experience and expertise is a significant asset of the program. CDP-1050 is a novel directed approach for the treatment of heart failure, and it is gratifying to be involved in what we hope will be a paradigm shift in this disease treatment."

"We are honored to be working with such knowledgeable and experienced individuals in the development of CDP-1050," said Amir Pelleg, Ph.D., Cordex's President and CSO. "Progressive heart failure is a growing and vexing medical problem around the world. It i
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/nqxxt3/biomarkers ... new report "Biomarkers - Technologies, Markets and ... This report follows the broad definition of a ... measured and evaluated as an indicator of normal ... responses to a therapeutic intervention. Tests based on ...
(Date:3/4/2015)... March 4, 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) ... completed a collaborative research program with Emerald ... Fast Collective Evolution Technology (FACET), Emerald Logic ... measurements obtained from each of 798 patients ... clinical trials ASSERT, SUSTAIN and ASSURE. The ...
(Date:3/4/2015)... Proove Biosciences , a ... excited to announce the launch of their CME-accredited ... Management of Pain”. , The continuing medical education ... next year. The focus of the program is ... pain treatments, integrate appropriate pain management techniques, and ...
(Date:3/4/2015)... NEWTOWN, Pa. , March 4, 2015 ... trials services and technology provider, today announced ... and 10 countries convened at its annual ... Spain to discuss the use ... development challenges. BioClinica,s eClinical technologies include: the ...
Breaking Biology Technology:Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3
... to empathize with others is partially determined by genes, ... of Wisconsin-Madison and Oregon Health and Science University (OHSU). ... mice learned to associate a sound played in a ... mouse in that cage respond with squeaks of distress. ...
... & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) ... (FDA) has asked for additional information regarding the ... CONSTA(R) (risperidone) Long-Acting Injection. The sNDA, submitted in ... adjunctive maintenance treatment to delay the occurrence of ...
... Life Sciences Companies to Accelerate Time to Value ... Inc., the global leader empowering enterprises to realize ... formation of a partnership with Ceiba Solutions, Inc., ... business application integrations to help customers achieve a ...
Cached Biology Technology:Mouse study reveals genetic component of empathy 2Mouse study reveals genetic component of empathy 3FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder 2FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder 3FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder 4FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder 5SciQuest Announces Strategic Alliance with Ceiba Solutions 2SciQuest Announces Strategic Alliance with Ceiba Solutions 3SciQuest Announces Strategic Alliance with Ceiba Solutions 4
(Date:2/5/2015)... TRIANGLE PARK, North Carolina , 5. ... sein 35. Jahr als spezialisiertes Logistikunternehmen und ... Position als einzige klinische Logistikfirma (Clinical Logistics ... Die Kernbotschaft der neuen Kampagne lautet ... und Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... , Jan. 26, 2015   Epic Sciences , a ... today announced that Murali Prahalad , Ph.D., president and ... World Conference (PMWC) 2015: Silicon Valley, which is taking ... View, Calif. on January 26-28, 2015. ... of Age as Biomarkers." Last year, Epic Sciences was a ...
(Date:2/5/2015)... Jan. 27, 2015   Marvin Test ... deployed, innovative test solutions for military, aerospace, ... of its TS-323 GENASYS Test Platform ... (LMSSC). GENASYS is a high-performance PXI-based system ... applications that require performance functional testing. GENASYS ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... linked to too much growth in patients has now ... the gene can lead to very different conditions, according ... Genetics . IMAGe* syndrome is a rare developmental ... than average body and organ size. Without treatment, the ...
... PHILADELPHIA By pairing an intimate knowledge of immune-system ... cross-disciplinary team at the University of Pennsylvania has arrived ... strategy to track down parasites that is similar to ... tuna use to hunt their prey. ...
... Researchers reporting online on May 24 in the Cell ... evidence that areas closed to all fishing are helping ... scientists applied a forensic DNA profiling approach to track ... of marine reserves on Australia,s Great Barrier Reef. , ...
Cached Biology News:Variations of a single gene can lead to too much or too little growth, study shows 2T cells 'hunt' parasites like animal predators seek prey, a Penn Vet-Penn Physics study reveals 2T cells 'hunt' parasites like animal predators seek prey, a Penn Vet-Penn Physics study reveals 3T cells 'hunt' parasites like animal predators seek prey, a Penn Vet-Penn Physics study reveals 4DNA evidence shows that marine reserves help to sustain fisheries 2
Immulon 1 B 1x12 Strip, flat bottom; consistent medium binding affinity for hydrophobic complexes and proteins....
The Holten Horizontal series of laminar airflow work benches offers comfort and ease of use....
...
Small bottle for hybridization 150 x 35mm...
Biology Products: